Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE: 603707)
Health Care · Pharmaceuticals · CN
CN¥8.18
-0.12% today · -20.7% 1Y
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHSE: 603707) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.97B and employs 1,558 people.
Over the last twelve months the share price has lost 20.7%, trading between 6.72 and 10.56.
Tweenvest scores Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. across four factors: quality 70/100, value 65/100, growth 18/100, dividend 23/100. Its strongest factor is quality.
603707 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.97B
- Revenue (TTM)
- $579.60M
- P/E
- 27.14
- EPS
- 0.30
- Dividend yield
- 1.22%
- Beta (5Y)
- 0.44
- 52-week high
- CN¥10.56
- 52-week low
- CN¥6.72
- Avg volume (3M)
- —
- Shares outstanding
- 1.61B
- Employees
- 1,558
- Next earnings
- —
About Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of drugs and APIs in China. It also provides heparin sodium, enoxaparin sodium, dalteparin sodium, nadroparin calcium, atracurium besylate, cisatracurium, calcium folinate, doxorubicin, milrinone, bleomycin, carboplatin, cytarabine, topotecan hydrochloride, phenylephrine hydrochloride, ganirelix acetate, furosemide, glycopyrrolate, neostigmine methylsulfate, succinylcholine chloride, reganosin, isoflurane blue, clofarabine, haloperidol decanoate, busulfan, gemcitabine hydrochloride, dexmedetomidine hydrochloride, nelarabine, rocuronium bromide, zoledronic acid, bupivacaine hydrochloride, plerixafor, eptifibatide, fondaparinux sodium, docetaxel, fluorouracil, palonosetron hydrochloride, oxaliplatin, fulvestrant, and adalimumab injections. The company offers bortezomib, bendamustine hydrochloride, mycophenolate mofetil, vancomycin hydrochloride, daptomycin, decitabine, voriconazole, tigecycline, melphalan hydrochloride, actinomycin, micafungin, azacitidine, pantoprazole sodium, mitomycin, pemetrexed disodium, thiotepa, and dacarbazine for injections. Its injection products cover anticoagulation, anti-tumor, cardiovascular disease, as well as surgical anesthesia, anti-bacterial infection, and angiography. The company was founded in 2000 and is headquartered in Nanjing, China.
- ISIN
- CNE100002WP3
- Founded
- 2000
- Listed since
- Jul 19, 2017
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Trulieve Cannabis Corp.NYSE: TRLV | $2.05B | $10.67 | +2.89% |
| Fujian Cosunter Pharmaceutical Co., Ltd.SZSE: 300436 | $2.04B | CN¥81.47 | -2.64% |
| Guobang Pharma Ltd.SHSE: 605507 | $2.00B | CN¥17.31 | -4.31% |
| PT Kalbe Farma Tbk.IDX: KLBF | $1.99B | Rp785.00 | +8.28% |
| Shenzhen Hepalink Pharmaceutical Group Co., Ltd.SZSE: 002399 | $1.95B | CN¥9.89 | +0.41% |
| Caplin Point Laboratories LimitedBSE: 524742 | $1.93B | Rs2,459.55 | -6.56% |
| Xeris Biopharma Holdings, Inc.NasdaqGS: XERS | $1.91B | $10.41 | -0.72% |
| Shenyang Xingqi Pharmaceutical Co.,Ltd.SZSE: 300573 | $1.90B | CN¥35.55 | -0.31% |
Figures last refreshed Oct 11, 2026.